Comparison of 2‐methoxyestradiol‐induced, docetaxel‐induced, and paclitaxel‐induced apoptosis in hepatoma cells and its correlation with reactive oxygen species

Previously, the authors observed that paclitaxel treatment of hepatoma cells resulted in differential cytotoxicity. Whether other antimicrotubule agents (docetaxel and 2‐methoxyestradiol) are more effective than paclitaxel is not clear. Moreover, whether the modulation of reactive oxygen species (ROS) is involved in the drug‐induced growth inhibition of hepatoma cells is not known.

[1]  N. Nagasue,et al.  Heterogeneity in androgen receptor levels and growth response to dihydrotestosterone in sublines derived from human hepatocellular carcinoma line (KYN-1). , 2008, Liver.

[2]  A. Ganser,et al.  Advanced head and neck cancer and clinical experience of an effective new agent: docetaxel. , 1998, Anticancer research.

[3]  M. Takada,et al.  Requirement of Caspase-3(-like) Protease-mediated Hydrogen Peroxide Production for Apoptosis Induced by Various Anticancer Drugs* , 1998, The Journal of Biological Chemistry.

[4]  C. Chi,et al.  Submicromolar paclitaxel induces apoptosis in human gastric cancer cells at early G1 phase. , 1998, Anticancer research.

[5]  C. Chi,et al.  Differential paclitaxel-induced cytotoxicity in rodent and human hepatoma cell lines. , 1998, Anticancer Research.

[6]  S. Horwitz,et al.  Mechanisms of Taxol-induced cell death are concentration dependent. , 1998, Cancer research.

[7]  J. Sparano.  Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. , 1998, Seminars in oncology.

[8]  W. Schmiegel,et al.  Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. , 1998, British Journal of Cancer.

[9]  G. Giaccone,et al.  Gemcitabine and paclitaxel combinations in non-small cell lung cancer. , 1998, Seminars in oncology.

[10]  H. Choy,et al.  Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  M. Marberger,et al.  Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial. , 1998, British Journal of Cancer.

[12]  J. Whang‐Peng,et al.  Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. , 1998, British Journal of Cancer.

[13]  J. Ajani,et al.  Phase II study of Taxol in patients with advanced gastric carcinoma. , 1998, The cancer journal from Scientific American.

[14]  H. Adlercreutz,et al.  2-Methoxyestradiol-induced phosphorylation of Bcl-2: uncoupling from JNK/SAPK activation. , 1998, Biochemical and biophysical research communications.

[15]  J. Crown,et al.  New chemotherapy combinations with docetaxel in the treatment of patients with non-small cell lung cancer. , 1998, Seminars in oncology.

[16]  Z. Werb,et al.  Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change. , 1998, Science.

[17]  R. James,et al.  Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Nishida,et al.  Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest. , 1998, Science.

[19]  G. Storz,et al.  Activation of the OxyR transcription factor by reversible disulfide bond formation. , 1998, Science.

[20]  V. Georgoulias,et al.  First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  R. Burns.  Structural biology: Synchronized division proteins , 1998, Nature.

[22]  D. Bell,et al.  An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. , 1997, Cancer research.

[23]  P. Fumoleau.  Efficacy and safety of docetaxel in clinical trials. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[24]  S Seeber,et al.  Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  D. Giachetti,et al.  Protection against oxidative damage of erythrocyte membrane by the flavonoid quercetin and its relation to iron chelating activity , 1997, FEBS letters.

[26]  Jesse D. Martinez,et al.  Free radicals generated by ionizing radiation signal nuclear translocation of p53. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[27]  S. Nattel,et al.  Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. , 1997, The New England journal of medicine.

[28]  H. Lander.  An essential role for free radicals and derived species in signal transduction , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  Y. Hiraku,et al.  Oxidative DNA damage and apoptosis induced by benzene metabolites. , 1996, Cancer research.

[30]  B. Chait,et al.  Redox regulation of cell signalling , 1996, Nature.

[31]  D. Kerr,et al.  Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  J. Whang‐Peng,et al.  Phase II study of flutamide in the treatment of hepatocellular carcinoma , 1996, Cancer.

[33]  J. Liehr,et al.  Inhibition of Catechol O-Methyltransferase-catalyzed O-Methylation of 2- and 4-Hydroxyestradiol by Quercetin , 1996, The Journal of Biological Chemistry.

[34]  V. Ferrans,et al.  Requirement for Generation of H2O2 for Platelet-Derived Growth Factor Signal Transduction , 1995, Science.

[35]  N. Nagasue,et al.  Androgen and oestrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: Impact on intrahepatic recurrence after hepatic resection , 1995, The British journal of surgery.

[36]  P. Vrignaud,et al.  Preclinical evaluation of docetaxel (Taxotere). , 1995, Seminars in oncology.

[37]  J. Yodoi,et al.  Persistent oxidative stress in cancer , 1995, FEBS letters.

[38]  H. Lehr,et al.  Vitamin C prevents cigarette smoke-induced leukocyte aggregation and adhesion to endothelium in vivo. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  F. Guengerich,et al.  Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. , 1994, Cancer research.

[40]  C. Nathan,et al.  Regulation of biosynthesis of nitric oxide. , 1994, The Journal of biological chemistry.

[41]  G M Bokoch,et al.  Regulation of the human neutrophil NADPH oxidase by the Rac GTP-binding proteins. , 1994, Current opinion in cell biology.

[42]  Michael S. Pepper,et al.  The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth , 1994, Nature.

[43]  J. Liehr,et al.  Quercetin increases the severity of estradiol-induced tumorigenesis in hamster kidney. , 1994, Toxicology and applied pharmacology.

[44]  Y. Lo,et al.  Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. , 1994, Biochemical pharmacology.

[45]  J. Robinson,et al.  Intracellular hydrogen peroxide and superoxide anion detection in endothelial cells , 1994, Journal of leukocyte biology.

[46]  C. J. Chen,et al.  Elevated serum testosterone levels and risk of hepatocellular carcinoma. , 1993, Cancer research.

[47]  G. Chau,et al.  Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection , 1992, Hepatology.

[48]  I. Ringel,et al.  Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. , 1991, Journal of the National Cancer Institute.

[49]  R. Donehower,et al.  Taxol: a novel investigational antimicrotubule agent. , 1990, Journal of the National Cancer Institute.

[50]  J. Korula,et al.  Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma. , 1988, Journal of clinical gastroenterology.

[51]  E. Nogales,et al.  Structure of the alpha beta tubulin dimer by electron crystallography. , 1998, Nature.

[52]  R. D'Amato,et al.  Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. , 1997, Cancer research.

[53]  S. Jay,et al.  Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. , 1997, The New England journal of medicine.

[54]  Yager Jd,et al.  Molecular Mechanisms of Estrogen Carcinogenesis , 1996 .

[55]  J. Yager,et al.  Molecular mechanisms of estrogen carcinogenesis. , 1996, Annual review of pharmacology and toxicology.

[56]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .

[57]  H. Lorenz,et al.  A rapid and simple method for the isolation of apoptotic DNA fragments. , 1994, Nucleic acids research.

[58]  C. N. Coleman,et al.  X-irradiation, phorbol esters, and H2O2 stimulate mitogen-activated protein kinase activity in NIH-3T3 cells through the formation of reactive oxygen intermediates. , 1994, Cancer research.

[59]  B R Goldspiel,et al.  Paclitaxel (Taxol) , 1994, Pharmacotherapy.

[60]  C. Rabito,et al.  Quantitation of intracellular oxidation in a renal epithelial cell line. , 1988, Free radical biology & medicine.